Tucidinostat

Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China.^[1] It was also known as HBI-8000.^[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.^[3]

Tucidinostat

Clinical data
Trade names	Epidaza, Hiyasta
Other names	Chidamide, HBI-8000
ATC code	L01XH06 (WHO)
Identifiers
IUPAC name N-(2-Amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
CAS Number	1616493-44-7 Y
PubChem CID	12136798
DrugBank	06334
ChemSpider	7976319
UNII	87CIC980Y0
KEGG	D10993
ChEMBL	ChEMBL3621988
CompTox Dashboard (EPA)	DTXSID701032295
Chemical and physical data
Formula	C22H19FN4O2
Molar mass	390.418 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
InChI InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+ Key:SZMJVTADHFNAIS-BJMVGYQFSA-N

Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.^{[2][better source needed]} In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.^[4]

Tucidinostat is being researched as a treatment for pancreatic cancer.^[5][6][7] However, it is not US FDA approved for the treatment of pancreatic cancer.